0.88

0.65% 0.0057

Pre-market: .87 -0.01 -1.14%

Scienture Holdings Inc (SCNX)

Overview News Price History Discussions Forecast

Scienture Holdings Inc stock is traded at $0.88, with a volume of 95,239. It is up +0.65% in the last 24 hours and down -7.47% over the past month. Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.

Previous Close:

$0.8743

Open:

$0.88

24h Volume:

95,239

Relative Volume:

0.04

Market Cap:

$11.55M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+0.41%

1M Performance:

-7.47%

6M Performance:

-88.59%

1Y Performance:

+0.00%

1-Day Range:

$0.85

$0.90

1-Week Range:

$0.831

$0.939

52-Week Range:

$0.69

$9.55

Scienture Holdings Inc Stock (SCNX) Company Profile

Name

Scienture Holdings Inc

Sector

Healthcare (1166)

Industry

Pharmaceutical Retailers (10)

Phone

(800) 261 0281

Address

2420 BRUNELLO TRACE, LUTZ

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SCNX's Discussions on Twitter

Compare SCNX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCNX Scienture Holdings Inc	0.88	11.67M	0	0	0	0.00
WBA Walgreens Boots Alliance Inc	11.20	9.69B	151.95B	-5.78B	571.00M	-6.69
HITI High Tide Inc	2.29	184.54M	376.07M	-22.41M	18.73M	-0.298
WGRX Wellgistics Health Inc	1.88	179.65M	0	0	0	0.00
PETS Petmed Express Inc	3.82	77.87M	270.52M	-6.08M	17.42M	-0.2944
HKPD Hong Kong Pharma Digital Technology Holdings Ltd	1.85	13.20M	0	0	0	0.00

Scienture Holdings Inc Stock (SCNX) Latest News

May 23, 2025

Scienture appoints Hariharan, Mani as co-CEOs - MSN

May 23, 2025

May 22, 2025

SCIENTURE Appoint Dr. Shankar Hariharan and Dr. Narasimhan Mani as Co-CEO’s - citybiz

May 22, 2025

Scienture Appoints Co-CEOs as Suren Ajjarapu Steps Down - marketscreener.com

May 22, 2025

SCIENTURE Announces Executive Leadership Transition | SCNX Stock News - GuruFocus

May 22, 2025

SCIENTURE Announces Executive Leadership Transition - The Manila Times

May 22, 2025

Scienture Holdings, Inc. Announces Leadership Transition as Suren Ajjarapu Steps Down as CEO and Chairman - Nasdaq

May 22, 2025

Scienture Names Two Pharma Veterans as Co-CEOs in Strategic Leadership Overhaul - Stock Titan

May 22, 2025

May 19, 2025

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, - GuruFocus

May 19, 2025

Scienture Holdings, Inc. Announces FDA Patent Listing for Arbli™, First FDA-Approved Liquid Losartan Formulation - Nasdaq

May 19, 2025

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. - The Manila Times

May 19, 2025

FDA Orange Book Milestone: First-Ever Liquid Losartan Secures Patent Protection Until 2041 - Stock Titan

May 19, 2025

Long-Term Bull Put Spread Provides Opportunities for ARM Bulls - The Globe and Mail

May 19, 2025

May 14, 2025

3 Consumer Discretionary Stocks to Buy in a Divided Economy - The Globe and Mail

May 01, 2025

Apr 22, 2025

Scienture Announces Manufacturing And Supply Chain Readiness For ArbliTM, (Losartan Potassium) Oral Suspension, 10Mg/Ml For A Target Product Launch In July 2025 - marketscreener.com

Apr 22, 2025

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - The Manila Times

Apr 22, 2025

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. | SCNX Stock News - GuruFocus

Apr 22, 2025

Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets - Stock Titan

Apr 22, 2025

Apr 11, 2025

Scienture Holdings Divests Subsidiaries to Tollo Health - MSN

Apr 11, 2025

Apr 08, 2025

Scienture Holdings divests subsidiaries for $5 million By Investing.com - Investing.com South Africa

Apr 08, 2025

Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M - TipRanks

Apr 08, 2025

Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million - marketscreener.com

Apr 08, 2025

Scienture Announces The Divestiture Of Its Legacy Subsidiaries - MarketScreener

Apr 08, 2025

Scienture Holdings divests subsidiaries for $5 million - Investing.com

Apr 08, 2025

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - The Manila Times

Apr 08, 2025

Strategic Pivot: Scienture Sells Healthcare IT Units for $5M, Doubles Down on Specialty Pharma - Stock Titan

Apr 08, 2025

Apr 05, 2025

SCNX stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com

Apr 04, 2025

SCNX stock touches 52-week low at $0.97 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 03, 2025

Scienture Holdings gears up for specialty pharma launches - Investing.com

Apr 03, 2025

Scienture CEO says focused on execution, growth, expansion for years ahead - TipRanks

Apr 03, 2025

Scienture Holdings gears up for specialty pharma launches By Investing.com - Investing.com UK

Apr 03, 2025

Scienture Holdings, Inc. Issues Annual Letter to Shareholders - TradingView

Apr 03, 2025

Major Pharma Transformation: Scienture Reveals Two FDA-Approved Drugs and $480M+ Market Opportunity - Stock Titan

Apr 03, 2025

Mar 26, 2025

Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register

Mar 26, 2025